Overall , nicotine replacement therapy , bupropion , and varenicline have all proven their effectiveness at either promoting smoking abstinence or a significant reduction in cigarette use
Smoking cessation is a chronic issue surrounding individuals with schizophrenia .
It is estimated that up to 90 % of patients diagnosed with schizophrenia smoke cigarettes .
The purpose of this article is to provide a non systematic review of the efficacy of  smoking cessation interventions as well as to explore the potential neuropsychiatric adverse effects of these agents in patients with schizophrenia .
The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia.
The purpose of this study was to determine the effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia . This was a longitudinal study and sixty-eight schizophrenic patients were assigned to 8 weeks of a nicotine-patch therapy program or a control group . The generalized estimating equation analysis revealed that there were significant reductions in the subjects ' nicotine dependence ( Fagerstrom Tolerance Question naire ) , the number of cigarettes per day , and CO levels over an 8-week period of nicotine-patch therapy and 3-month follow-up . The point-prevalence rates of abstinence from smoking were an abstinence of 26.9 % at 8 weeks and 26.9 % at a 3-month follow-up . At the 3-month follow-up , the rate of continuous smoking abstinence in the nicotine-patch group was 23.1 %
Overall , nicotine replacement therapy , bupropion , and varenicline have all proven their effectiveness at either promoting smoking abstinence or a significant reduction in cigarette use
Smoking cessation is a chronic issue surrounding individuals with schizophrenia .
It is estimated that up to 90 % of patients diagnosed with schizophrenia smoke cigarettes .
The purpose of this article is to provide a non systematic review of the efficacy of  smoking cessation interventions as well as to explore the potential neuropsychiatric adverse effects of these agents in patients with schizophrenia .